607.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$605.61
Aprire:
$606.89
Volume 24 ore:
244.19K
Relative Volume:
0.25
Capitalizzazione di mercato:
$65.95B
Reddito:
$14.09B
Utile/perdita netta:
$4.50B
Rapporto P/E:
15.47
EPS:
39.28
Flusso di cassa netto:
$2.96B
1 W Prestazione:
-0.49%
1M Prestazione:
+6.01%
6M Prestazione:
-26.71%
1 anno Prestazione:
-36.48%
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
REGN
Regeneron Pharmaceuticals Inc
|
607.27 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
504.46 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
ARGX
Argen X Se Adr
|
655.81 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
269.52 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
253.49 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2025-01-16 | Downgrade | UBS | Buy → Neutral |
2024-12-10 | Ripresa | BofA Securities | Underperform |
2024-11-15 | Iniziato | Wolfe Research | Outperform |
2024-11-14 | Iniziato | Citigroup | Neutral |
2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
2024-03-12 | Iniziato | Bernstein | Outperform |
2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2023-11-09 | Iniziato | Deutsche Bank | Hold |
2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
2023-08-21 | Reiterato | Oppenheimer | Perform |
2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
2022-06-06 | Iniziato | Jefferies | Underperform |
2022-05-23 | Iniziato | SVB Leerink | Outperform |
2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
2021-12-09 | Ripresa | Wells Fargo | Overweight |
2021-12-07 | Ripresa | Cowen | Market Perform |
2021-12-06 | Iniziato | Goldman | Buy |
2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
2021-06-29 | Iniziato | H.C. Wainwright | Buy |
2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
2020-04-08 | Iniziato | The Benchmark Company | Hold |
2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
2020-02-27 | Iniziato | Barclays | Overweight |
2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
2020-02-11 | Aggiornamento | Argus | Hold → Buy |
2019-12-24 | Iniziato | Raymond James | Mkt Perform |
2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2019-11-12 | Iniziato | SunTrust | Hold |
2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
2019-10-17 | Ripresa | BofA/Merrill | Neutral |
2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Aspire Growth Partners LLC Makes New $421,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mercer Global Advisors Inc. ADV Has $16.66 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Retinal Vein Occlusion Market Size, Trends & Growth Forecast - openPR.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Earnings Miss - MarketBeat
TD Waterhouse Canada Inc. Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Voleon Capital Management LP Acquires Shares of 671 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by The Manufacturers Life Insurance Company - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Misses Estimates By $0.61 EPS - MarketBeat
Northern Trust Corp Has $751.39 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria - MSN
Cantor Fitzgerald Issues Positive Outlook for REGN Earnings - MarketBeat
Westbourne Investments Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to “Hold” at StockNews.com - Defense World
Regeneron (REGN) Declares Quarterly Dividend of $0.88/Share - GuruFocus
Retinal Vein Occlusion Market Projected To Witness Massive - openPR.com
Schonfeld Strategic Advisors LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
AQR Capital Management LLC Sells 18,449 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition - insights.citeline.com
FY2025 EPS Estimates for REGN Raised by Cantor Fitzgerald - Defense World
Regeneron announces significant expansion of US manufacturing capacity - The Manufacturer
Aquatic Capital Management LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences - simplywall.st
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’ - MSN
Regeneron Pharmaceuticals (REGN) Price Target Lowered by Guggenh - GuruFocus
Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea - Seeking Alpha
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Regeneron to present new cancer treatment data at ASCO By Investing.com - Investing.com India
Regeneron to present new cancer treatment data at ASCO - Investing.com
Regeneron (REGN) to Unveil Key Oncology and Hematology Data at A - GuruFocus
Regeneron (REGN) to Showcase Dupixent Data at 2025 ATS Conferenc - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Revenue Concerns | - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Revenue Concerns | REGN Stock News - GuruFocus
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination - The Manila Times
Regeneron Pharmaceuticals to Present New Oncology and Hematology Data at 2025 ASCO Annual Meeting - Nasdaq
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases - Stock Titan
PDT Partners LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron (REGN) Faces Price Target Cut Amid Eylea Challenges | - GuruFocus
California State Teachers Retirement System Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Public Employees Retirement Association of Colorado - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Beacon Pointe Advisors LLC - MarketBeat
Stifel Financial Corp Has $27.13 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
MML Investors Services LLC Purchases 2,218 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years - Insider Monkey
Cantor Fitzgerald maintains Regeneron stock with $695 target By Investing.com - Investing.com South Africa
Robert W. Baird Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Another Regeneron CRL Prompts Regulatory Operations Questions - insights.citeline.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Shares Are Up Today: What's Going On? - Benzinga
Guggenheim Cuts Regeneron Pharmaceuticals' Price Target to $810 From $940 - marketscreener.com
Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):